Technology
TraffikGene is determined to overcome many of the current nucleic acid therapeutics (mRNA, siRNA, ASOS) delivery limitations leveraging on a conceptually new proprietary delivery technology platform.
TraffikGene’s non-viral carriers are based on short, synthetic peptide scaffolds, which can be robotically synthetised and scaled up from readily accessible building blocks.
- A single carrier is able to deliver nucleic acid payloads without additional components in the formulation, facilitating the carrier-cargo mixing step as well as carrier discovery and optimisation processes.
- Both cargo-specific and broadly applicable carriers are identified after screening.
- TraffikGene enables the delivery of different cargos: mRNA, siRNA, DNA, CRISPR/Cas.
- Administration through different routes is possible both for local and systemic applications in vivo.
- TraffikGene’s platform is applicable to a variety of therapeutic applications: vaccination, immunotherapy, rare diseases.
TraffikGene allows targeting potential via two independent or combined approaches:
- Physicochemical targeting: Fine-tuning of nanoparticle formulation properties (i.e., size, surface potential).
- Molecular targeting: Through the incorporation of naturally occurring targeting sequences Via the straightforward attachment of chemical moieties on the peptide scaffold (e.g., small molecules, probes, targeting ligands).
TraffikGene carriers’ chemical properties maximise efficacy, while avoiding toxicity concerns.
- Transiently amphiphilic carriers designed to disassemble at endosomal acidic pH into simple, easily processable by-products.
- Fully synthetic, non-viral, and PEG-free systems.
- Non-immunogenic carriers allow repeated dosing regimes.
The chemical approach employed during the synthesis of carrier libraries accelerates developments by:
- Automation in synthesis and formulation steps.
- Single carrier formulations, no additives required.
- Discovery by High-Throughput Screening.
- Machine learning for structure-activity refinement and prediction.
Discovery
Lead optimization
IND-enabling
Clinical Phase 1/2
Oncology
Therapeutic mRNA vaccine
(own development)
CAR T solid tumor
(collaboration with EIC Pathfinder public-private consortium)
Antisense-based therapy
(collaboration with CRG)
Metabolic diseases
Lysosomal storage disorder
(collaboration with IDIS)
Partnering opportunities
Are you developing an innovative nucleic acid therapeutic but lack a suitable delivery tool to take it to its site of action? Having trouble in-licensing mainstream delivery technologies due to their complex intelectual property landscape?
At TraffikGene® we are willing to help you address your delivery needs employing our proprietary technology. Clearly differentiated from competing delivery approaches, TraffikGene carriers offer attractive potential for collaboration due to the layered intellectual property approach we are developing, facilitating licensing schemes.
Also, our platform approach takes advantage on the unique chemical properties of our carriers and their tunability, which allows for tailored screening and optimization processes to find optimal carrier characteristics, such as a certain targeting, PK or cargo selectivity.
